EvaluatePharma - Merck & Co - Worldwide

Merck & Co

All Financial Data in US $ (mln)

Worldwide

Overview

Company News

Karo Bio Announces That Merck Discontinues Development of MK-6913 for Hot Flashes
Karo Bio (September 08, 2010)

Merck Receives Approval from FDA for Expanded Indications for Atypical Antipsychotic Medication SAPHRIS® (asenapine) Sublingual Tablets
Merck & Co (September 07, 2010)

Daily Market Movers (2 Sep 2010)

(September 03, 2010)

Cardiome Achieves $30 Million Milestone
Cardiome Pharma (September 02, 2010)

Faes Farma Enters Into the Diabetes Market
Faes Farma (September 02, 2010)

BRINAVESS(™) (vernakalant) for Infusion Approved in the European Union for Rapid Conversion of Recent Onset Atrial Fibrillation
Cardiome Pharma (September 01, 2010)

BRINAVESS(™) (vernakalant) for Infusion Approved in the European Union for Rapid Conversion of Recent Onset Atrial Fibrillation
Merck & Co (September 01, 2010)

From Oranienburg to the Rest of the World: Global Market Launch of Daxas® (Roflumilast) Kicks Off in Germany
Nycomed (September 01, 2010)

Portola Pharmaceuticals Announces Presentation of New Pharmacodynamic Data from Phase 2 Trial of Investigational Factor Xa Inhibitor, Betrixaban
Portola Pharmaceuticals (August 29, 2010)

Genetic Substudy Shows Fewer Major Cardiovascular Events With Ticagrelor (BRILINTA) Regardless Of Relevant Genetic Variability In ACS Patients
AstraZeneca (August 29, 2010)

Displaying 10 out of a possible 1964 unique stories.
Results Sorted By date
Display All Stories

EvaluatePharma® - the premier source for pharma and biotech analysis.

Expert integration of financial and product data across historic and forecast timeframes (1986 to 2016) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status, deals, license revenues and much more.

Company Profile



Profile	Merck & Co (MRK), a global provider of pharmaceutical products. 3 NOV 2009: Merck & Co acquired Schering-Plough in a reverse takeover in which Schering-Plough will remain as the surviving company, trading under the name Merck & Co. Upon closing of the transaction, Merck shareholders own approximately 68 percent of the combined company, and Schering-Plough shareholders are expected to own approximately 32 percent. Merck Chairman, President and Chief Executive Officer Richard T. Clark will lead the combined company.
Listed or Private Company	Listed
Company Classification	Global Majors
Company Website	Website

Full Company Profile Information

EventAnalyzer - Last Key Event


Closing Price DateClosing Price Date	EventAnalyzer Note	Market Cap (US $m)	Change (%)	Change (+$m)
9/2/2010	2 Sep: Company postpones plans to close some of its Dutch operations and negotiates with executives and workers on potential alternatives, including a sale of the R&D site.	108,652	-0.8%	-829

Top 3 Products (Worldwide Sales 2007/08)

				Annual Sales WW - Sales		Growth per Year (%)
Rank¹	Product	Generic Name	Therapeutic Subcategory	2007	2008	2008
1	Singulair	montelukast sodium	Anti-leukotrienes	4,266²	4,337	+2%
2	Cozaar	losartan monopotassium	Angiotensin II antagonists	3,350³	3,558	+6%
3	Fosamax	alendronate sodium	Bone calcium regulators	3,049⁴	1,553⁵	-49%

Note: Shaded Cells⁶

RX Sales Chart

Merck & Co	Data		Growth
	2007	2008	2008
Revenues By Segment
Pharmaceuticals
Pharmaceuticals Sales (In-depth)
Rx & OTC Pharmaceuticals
Prescription (Rx) Pharmaceuticals	25,824⁷	25,434⁸	-2%

Therapy Area Focus in 2008

Merck & Co
	2008
WW Rx & OTC Sales By Therapy Area
Main Categories
Cardiovascular⁹	4,786¹⁰
Central Nervous System	529
Dermatology	429
Endocrine	1,748
Gastro-Intestinal¹¹	307
Genito-Urinary	324
Musculoskeletal¹²	1,990¹³
Oncology & Immunomodulators	203
Respiratory¹⁴	4,337¹⁵
Sensory Organs¹⁶	914¹⁷
Systemic Anti-Infectives¹⁸	6,475¹⁹
Other Rx & OTC Pharma	3,499²⁰

EvaluatePharma® Coverage of Marketed and Pipeline Products


	Product Count
Merck & Co ²¹	636

2009 Product Sales analysis
2009 Pharmaceutical Sales
2009 Market Share & Global Ranking
Download to Excel
Search 2 yrs of company press releases


EP Vantage - last 6 months

Preview - ESC to throw up more than just the hot topics (August 26, 2010)

Therapeutic focus - What are plan B options if A-beta Alzheimer's hypothesis is void? (August 19, 2010)

Merck calls a go-slow on oral vernakalant (August 12, 2010)

Merck playing catch-up with boceprevir hep C data (August 05, 2010)

Merck continues to play down J&J arbitration but risk remains (August 03, 2010)

Displaying 5 out of a possible 33 unique stories.
Results Sorted By date
Display All Stories

Ranked on:
Annual Sales WW
2008

Group Total: Equals the sum of values in report based on report grouping.

Note: Where Top 5,10,100 etc filters have been applied, the aggregate value relates to the total of the original unfiltered group - not the displayed filtered data. Where n/a appears, a value has been hidden but is included in Group Total.

Examples:

e.g. Top 100 drugs reports. These are not grouped but are filtered to show only the top 100 products by sales in a particular year. The Group Total displayed is equal to the sum of all data within Evaluate Pharma - not just the top 100 products i.e. total market size.

e.g. Global Majors - Top 10 products. Report is grouped by Company and filtered to show only the top 10 products by sales in a particular year. Group Totals are displayed for each company and are equal to the sum of all available data for that company - not just the top 10 products.

XXXXXXX XXXXXXX:

XXXXXX: XX XXXX XXXXXXX (XX XXX XXXX):
XXXX-XXXX XXXXXXXXX XXXXX XXX XXXX XX XXXXXXXXX XXXX $X.X XXXXXXX, X XX XXXXXXX XXXXXXXX XXXXXXXX XXXX XXX XXXXX XXXX. XXXXXXXXX XXXXXXXXX XX XX XXX XX. X XXXXXXXXXX XXXXXXX XX XXX X.X. XXXXXXXXXXX XXXXXX.

XXXXXXX XXXXXXX:

XXXXXX: XX XXXX XXXXXXX (XX XXX XXXX):
XXXXXX XXXXX XX XXXXX'X XXXXXXXXXXXXXXXX XXXXXXXXX, XXXXXX XXX XXXXXX, XXXX $XXX XXXXXXX XXX XXX XXXXXX XXXXXXX XX XXXX, X X XXXXXXX XXXXXXXX XXXXXXXX XXXX XXX XXXXXX XXXXXXX XX XXXX. XXXXXX XXXXX XXXX $X.X XXXXXXX XXXXXX XXXX, X X XXXXXXX XXXXXXXX XXXXXXXX XXXX XXXX-XXXX XXXX. XXXXXX XXX XXXXXX XXX XXXXX XXX XXXXXXX XXXXXXX XX XXX XXXXXXXXXXX XXXXXXXX XXXXXXX XXXXX XX XXXXXXXXX.

Company Specific NameAtherosclerosis; Hypertension/heart failure

XXXXXXXX XXXXXXX:
XXXXXXX XXXXXXXXXXX XX XXXX XX-X.

XXXXXXXX XXXXXXX:
XXXXX XXXXXXX XXXXXXX XXXX XXXXXX & XXXXXXXXX.

XXXXXXX XXXXXXX:

XXXXXX: XX XXXX XXXXXXX (XX XXX XXXX):
XXXXXXXXX XXXXX XX XXXXXXX XXX XXXXXXX XXXX X (XXXXXXXX XX XXXXXXXXX XXXXXXXXXX XXX XXXXXXXX XXXXX) XXXX $XXX XXXXXXX XXX XXX XXXXXX XXXXXXX XX XXXX, XXXXXXXXXXXX XX XXXXXXXX XX X XXXXXXX XXXXXXXX XXXX XXX XXXXXX XXXXXXX XX XXXX. XXXXXXXXX XXXXX XXX XXX XXXX XXXX $X.X XXXXXXX, X X XXXXXXX XXXXXXXX XXXXXXXX XXXX XXX XXXXX XXXX. XXXXXXX XXXX XXXX X.X. XXXXXXXXX XXXXXXXXXXX XX XXXXXXXX XXXX. XXXXXXX XXXX X XX XX/XXXX XX XXXXXXXXXXX XXXX XXXX X.X. XXXXXX XXXXXXXXXXX XX XXXXX XXXX. XXX XXXXXXX XXXXXXXXXXX X XXXXXXXXXXX XXXXXXX XX XXXXX XX XXX XXXXXX XXXXXX XX XXXXXXX XXX XXXXXXX XXXX X XXXXX XXXX XXXXXXX'X XXXX XX XXXXXX XXXXXXXXXXX.

XXXXXXXX XXXXXXX:
XXXXX XXXXXXX XXXXXXX XXXX XXXXXX & XXXXXXXXX.

XXXXX XXXXXXX XXX XXXX XX XXXXXX XXXXXXX XXX XXXX-XXXXXX XXXXXXXXXXX.

Shaded Cells

A shaded cell signifies potentially incomplete data. E.g. A shaded cell in "Change (+/-)" means there is no corresponding value, i.e. there is data for 2001, but no data for 2000. This could signify a product launch, first time disclosure of sales, a product acquisition or missing data.

A shaded cell containing n/a signifies valid data followed by blank or zero values. E.g. A shaded cell containing n/a in "Change (+/-)" means a value is present for 2000, but blank for 2001. This could signify a product disposal / withdrawal, discontinuation of disclosure or missing data.

XXXXXXXX XX $X:
X) +XXXXX.X XXXXX XXXXX.
X) +XXXX.X (XXXXX-XXX XXXXX XXXXXXX XXX XXX XXXXXXXX; XXXXXX XXXXXXX-XXX & XXX-XXX XX XXX XXXXX), XX% XX XXXXXXXXXXXXXX XX'X.

XXXXX
X) XXXXXXXXXXX XXXXXX XXXXXX (XXXX. XXXXXX & XXXXXXXX XXXXXXX)
X) XX% XX XXX XXXXX XXX XX XXXXX XX X. XXXXXXX.
XXXXXXXXX: (XXXXXX XX & XXXXXXX) & + XXXXX.

Company Specific NameAnti-ulcerants

Company Specific NameOsteoporosis; Anti-inflammatories/analgesics

XXXXXXXX XXXXXXX:
XXXXXXX XXXXXXXXXXX XX XXXX XX-X.

Company Specific NameRespiratory

XXXXXXXX XXXXXXX:
XXXXXXX XXXXXXXXXXX XX XXXX XX-X.

Company Specific NameOphthalmologicals

XXXXXXXX XXXXXXX:
XXXXXXX XXXXXXXXXXX XX XXXX XX-X.

Company Specific NameVaccines/biologicals; Antibiotics; Human immunodeficiency virus (HIV) + 50% of PM-MSD Vaccines JV

XXXXXXXX XXXXXXX:
XXXXXXX XXXXXXXXXXX XX XXXX XX-X.

XXXXXX XX XXXXXXX:
XXXXX XXXXXXXXXXXXXXX (XXXXXXXXX XXXXXXX)
XXXX
XX% XXXXXXXXXXXXXX XXXXX XXXXXXXX (XXXX. XXXXX-XXX XX XX X. XXXXXXX, XXX XXX XXXXXXXX & XXXXXX XXXXXXX-XXX XXX XXXXXXXX.)

XXXXX
XXXXXXXXXXX XXXXX XXXXXXXX (XXXXXXXXX XXXXXXX)

XXXXX
XXXXXXXXXXX XXXXXX XXXXXX (XXXX. XXXXXX & XXXXXXXX XXXXXXX)